Walk through the websites of any dozen research peptide vendors and you'll see a familiar parade of claims: "97% pure," "98% purity guaranteed," "98%+ HPLC tested." On the surface those numbers sound close to 99%. Mathematically, they're not. This article makes the case that purity below 99% should be a deal-breaker for any serious buyer, and explains why the missing percentage points usually represent more than the marketing language suggests.
The math: how much actual impurity are you getting?
Let's run a 10mg vial through three different purity grades and look at what's actually in each one.
| Stated purity | Target compound | Impurities |
|---|---|---|
| 95% | 9.5 mg | 0.5 mg |
| 97% | 9.7 mg | 0.3 mg |
| 98% | 9.8 mg | 0.2 mg |
| 99% | 9.9 mg | 0.1 mg |
| 99.5% | 9.95 mg | 0.05 mg |
Going from 99% to 95% sounds like a 4-point drop. In terms of actual impurity content, it's a 5x increase. A 95%-pure sample contains five times the impurity load of a 99%-pure sample of the same mass.
Now consider that the "impurity" portion isn't a single homogeneous substance. It's typically a mixture of:
- Truncated sequences — peptides that were almost-but-not-quite the full target (a missing amino acid, an incomplete coupling step)
- Deletion sequences — variants where one or more residues were skipped during synthesis
- Side-reaction byproducts — molecules formed by unintended chemistry during synthesis
- Residual protecting groups — small molecules left over from the synthesis
- Counter-ions — the salts the peptide is paired with (TFA, acetate, etc.)
- Residual solvents — trace organic solvents from purification
- Degradation products — byproducts of the synthesis or of subsequent storage
For research applications, every category in that list is a problem in different ways. Truncated sequences may have biological activity that's similar but not identical to the target — confounding any cell-based assay. Side reactions can produce molecules that bind the same receptors but with different affinity. Residual solvents can be cytotoxic at concentrations researchers don't expect.
When a vendor reports 95% purity, they're saying: "5% of what's in this vial is some combination of these failure modes, and we either haven't characterized it or aren't telling you what."
Why 99% is a meaningful threshold, not a marketing line
Here's the practical reason 99% matters specifically:
Modern peptide synthesis has been able to achieve 99%+ purity reliably for decades. Solid-phase peptide synthesis (SPPS) coupled with proper HPLC purification can produce 99%+ pure peptides routinely for sequences up to about 50 amino acids. The chemistry isn't experimental — it's well-established industry practice.
When a vendor sells material at 95% or 97%, it generally means one of three things:
- They didn't purify the crude synthesis enough. Skipping or shortening the HPLC purification step is faster and cheaper.
- They're sourcing from a manufacturer that doesn't do enough QC. Some Chinese and Indian raw material suppliers run synthesis at scale without rigorous purification, then sell the bulk material to resellers at low cost.
- They used the cheapest possible raw materials and didn't bother re-testing. They're trusting the manufacturer's claims without independent verification.
None of those are good answers if you're paying premium prices.
The "but it's research, not pharma" pushback
A common response when this comes up is: "These are research peptides, not pharmaceuticals. The standards are different." The argument goes that pharmaceutical-grade purity is overkill for in vitro research.
That's partially true and partially a cop-out. It's true that the FDA's specific approval criteria for human therapeutics don't apply to research compounds. But it's a cop-out because:
- Research data quality depends on input quality. If your in vitro assay is supposed to measure how a specific peptide affects a cell line, and 5% of what you're adding is something else, your data is contaminated by definition.
- Reproducibility crisis. A huge fraction of failed reproductions in biology research trace to contaminated reagents and impure compounds. Cutting corners on purity directly worsens that problem.
- Cell toxicity from side-reaction byproducts. Many synthesis byproducts have non-specific biological activity. They can cause cell stress, off-target binding, or false-positive results in assays.
The "it's just research" framing is often used by vendors who don't want to invest in proper purification. The customers who actually do serious research know better.
What to look for instead
If you're evaluating a peptide vendor, the relevant questions aren't just about the stated number:
- What's the actual measured purity, with two decimal places? A vendor confident in their material reports 99.5% or 99.8% — not "99%+" with the implication anywhere from 99.0% to 100% would qualify.
- Where's the chromatogram? Real data shows the breakdown. A purity number without supporting visuals is asking for trust without offering verification.
- What was the worst result they've seen on this product? A vendor that occasionally ships 99.6% but sometimes ships 99.0% is honest about variation. A vendor who claims a perfect 99.9% on every batch is overstating consistency.
- Who did the testing? The same questions from our previous post on COAs apply: independent third-party labs are the gold standard, internal testing is suspect.
- What happens when they hit a sub-99% batch? Good vendors send it back to the manufacturer. Mediocre vendors sell it anyway because the customer probably won't notice.
Our standard
Our internal threshold is 99.0% minimum purity, with the actual number from each batch reported on the COA. We typically see 99.5%-99.8% on most products. Anything that tests below 99.0% goes back to the manufacturer and never enters our shipping inventory.
This isn't because we think 99.0% is a magic number. It's because the modern peptide industry can routinely deliver above that threshold, and accepting anything less means accepting either lazy purification or weak quality control somewhere in the supply chain.
Bottom line
The difference between 99% and 97% purity is bigger than it looks. Numerically it's only 2 points, but it represents a 3x increase in impurity load, with that impurity being a poorly-characterized mixture of synthesis byproducts that can confound your research.
For a deeper look at how purity gets measured in the first place, see What Is HPLC Testing and Why It Matters for Peptide Purity. For our specific purity standard and the lab partnership behind it, see the Quality & Testing page.